Group 1: Company Overview - Proris is a data-driven clinical research service provider focused on patient-centered approaches, aiming to enhance the efficiency of clinical trials in China [1] - As of Q3 2025, the company achieved a revenue of CNY 219 million, representing a year-on-year growth of 9.84% [1] - For the first three quarters of 2025, total revenue reached CNY 609 million, with a net profit of CNY 87.38 million, up 20.92% year-on-year [2] Group 2: Financial Performance - The net profit for Q3 2025 was CNY 33.23 million, showing a significant increase of 91.60% year-on-year [2] - The company’s non-recurring net profit for the same period was CNY 31.13 million, reflecting a growth of 120.72% [2] - Cumulative service projects exceeded 4,200, with 2,538 active projects and a workforce of 4,271 employees [2] Group 3: Market Position and Strategy - Proris has established partnerships with major pharmaceutical companies, including the top 10 global pharmaceutical firms, enhancing its service capabilities in innovative drug projects [3] - The company is focused on digitalization and smart technology to improve clinical trial management efficiency [3] - The domestic innovative drug market is experiencing rapid growth, with 76 new drugs approved in 2025, marking a historical high [2] Group 4: Future Outlook - The company plans to continue its recruitment and training efforts to align with market demands and regulatory standards, ensuring a robust talent pipeline for future growth [3] - The innovative drug industry in China is expected to positively impact the clinical research outsourcing business, driven by policy, funding, and technology advancements [2]
普蕊斯(301257) - 301257普蕊斯投资者关系活动记录表20260116